Methods and compositions for modulating splicing

A compound of Formula (II), or a pharmaceutically acceptable salt thereof:

• wherein,
• A is —CRA═CRA—;
• E is —NR—;
• each RA is hydrogen or deuterium;
• ring Q is
• wherein each RQ is independently selected from hydrogen, deuterium, and —F;
• and
• ring P is phenyl or 5-6-membered monocyclic heteroaryl, wherein the monocyclic heteroaryl contains 0-4 N atoms, 0-1 O atoms, 0-1 P atoms, and 0-1 S atoms in the ring, and the monocyclic heteroaryl contains at least one heteroatom;
• and wherein the phenyl or monocyclic heteroaryl is optionally substituted with one or more substituents selected from the group consisting of halogen, —CN, —NH2, oxo, —OH, —CO2H, —CO2(C1-C4alkyl), —C(═O)NH2, —C(═O)NH(C1-C4 alkyl), —C(═O)N(C1-C4alkyl)2, C1-C4alkyl, C1-C4 fluoroalkyl, C1-C4 heteroalkyl, and C1-C4 alkoxy;
• X is —O—;
• Z is CR2;
• W is C1-C3 alkylene or C1-C2 heteroalkylene, wherein the alkylene or heteroalkylene is optionally substituted with one or more F;
• R is hydrogen;
• R2 is hydrogen or deuterium;
• each R11, R12, R13, R14, R19, and R20 is independently selected from the group consisting of hydrogen, deuterium, F, C1-C4 alkyl, C1-C4 fluoroalkyl, and C1-C4 heteroalkyl;
• R16 is F and R17 is hydrogen;
• or R16 is hydrogen and R17 is F;
• R15 and R18 (i) are the same and selected from the group consisting of hydrogen and deuterium, or (ii) are the same and selected from the group consisting of F and C1-C4 alkyl;
• a is 0;
• b is 0;
• c is 1;
• and
• d is 1.